166 related articles for article (PubMed ID: 26526943)
1. mTORC2 and Metabolic Reprogramming in GBM: at the Interface of Genetics and Environment.
Masui K; Cavenee WK; Mischel PS
Brain Pathol; 2015 Nov; 25(6):755-9. PubMed ID: 26526943
[TBL] [Abstract][Full Text] [Related]
2. mTORC2 in the center of cancer metabolic reprogramming.
Masui K; Cavenee WK; Mischel PS
Trends Endocrinol Metab; 2014 Jul; 25(7):364-73. PubMed ID: 24856037
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness.
Artinian N; Cloninger C; Holmes B; Benavides-Serrato A; Bashir T; Gera J
J Biol Chem; 2015 Aug; 290(32):19387-401. PubMed ID: 25998128
[TBL] [Abstract][Full Text] [Related]
4. mTORC2 activity in brain cancer: Extracellular nutrients are required to maintain oncogenic signaling.
Masui K; Shibata N; Cavenee WK; Mischel PS
Bioessays; 2016 Sep; 38(9):839-44. PubMed ID: 27427440
[TBL] [Abstract][Full Text] [Related]
5. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance.
Masui K; Tanaka K; Ikegami S; Villa GR; Yang H; Yong WH; Cloughesy TF; Yamagata K; Arai N; Cavenee WK; Mischel PS
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9406-11. PubMed ID: 26170313
[TBL] [Abstract][Full Text] [Related]
6. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
7. mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT.
Gu Y; Albuquerque CP; Braas D; Zhang W; Villa GR; Bi J; Ikegami S; Masui K; Gini B; Yang H; Gahman TC; Shiau AK; Cloughesy TF; Christofk HR; Zhou H; Guan KL; Mischel PS
Mol Cell; 2017 Jul; 67(1):128-138.e7. PubMed ID: 28648777
[TBL] [Abstract][Full Text] [Related]
8. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc.
Masui K; Tanaka K; Akhavan D; Babic I; Gini B; Matsutani T; Iwanami A; Liu F; Villa GR; Gu Y; Campos C; Zhu S; Yang H; Yong WH; Cloughesy TF; Mellinghoff IK; Cavenee WK; Shaw RJ; Mischel PS
Cell Metab; 2013 Nov; 18(5):726-39. PubMed ID: 24140020
[TBL] [Abstract][Full Text] [Related]
9. Role of mTOR in glioblastoma.
Duzgun Z; Eroglu Z; Biray Avci C
Gene; 2016 Jan; 575(2 Pt 1):187-90. PubMed ID: 26341051
[TBL] [Abstract][Full Text] [Related]
10. mTORC2 dictates Warburg effect and drug resistance.
Masui K; Cavenee WK; Mischel PS
Cell Cycle; 2014; 13(7):1053-4. PubMed ID: 24583874
[No Abstract] [Full Text] [Related]
11. Novel Strategies to Discover Effective Drug Targets in Metabolic and Immune Therapy for Glioblastoma.
Wang G; Fu XL; Wang JJ; Guan R; Tang XJ
Curr Cancer Drug Targets; 2017; 17(1):17-39. PubMed ID: 27562399
[TBL] [Abstract][Full Text] [Related]
12. Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions.
Agnihotri S; Zadeh G
Neuro Oncol; 2016 Feb; 18(2):160-72. PubMed ID: 26180081
[TBL] [Abstract][Full Text] [Related]
13. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
14. Phosphoproteomic Analysis Defines BABAM1 as mTORC2 Downstream Effector Promoting DNA Damage Response in Glioblastoma Cells.
Kalpongnukul N; Bootsri R; Wongkongkathep P; Kaewsapsak P; Ariyachet C; Pisitkun T; Chantaravisoot N
J Proteome Res; 2022 Dec; 21(12):2893-2904. PubMed ID: 36315652
[TBL] [Abstract][Full Text] [Related]
15. The miR-491-3p/mTORC2/FOXO1 regulatory loop modulates chemo-sensitivity in human tongue cancer.
Zheng G; Jia X; Peng C; Deng Y; Yin J; Zhang Z; Li N; Deng M; Liu X; Liu H; Lu M; Wang C; Gu Y; He Z
Oncotarget; 2015 Mar; 6(9):6931-43. PubMed ID: 25749387
[TBL] [Abstract][Full Text] [Related]
16. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
17. PIH1D1 interacts with mTOR complex 1 and enhances ribosome RNA transcription.
Kamano Y; Saeki M; Egusa H; Kakihara Y; Houry WA; Yatani H; Kamisaki Y
FEBS Lett; 2013 Oct; 587(20):3303-8. PubMed ID: 24036451
[TBL] [Abstract][Full Text] [Related]
18. mTOR in aging, metabolism, and cancer.
Cornu M; Albert V; Hall MN
Curr Opin Genet Dev; 2013 Feb; 23(1):53-62. PubMed ID: 23317514
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of RND3/RhoE in glioblastoma patients promotes tumorigenesis through augmentation of notch transcriptional complex activity.
Liu B; Lin X; Yang X; Dong H; Yue X; Andrade KC; Guo Z; Yang J; Wu L; Zhu X; Zhang S; Tian D; Wang J; Cai Q; Chen Q; Mao S; Chen Q; Chang J
Cancer Med; 2015 Sep; 4(9):1404-16. PubMed ID: 26108681
[TBL] [Abstract][Full Text] [Related]
20. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance.
Wu SH; Bi JF; Cloughesy T; Cavenee WK; Mischel PS
Cancer Biol Med; 2014 Dec; 11(4):255-63. PubMed ID: 25610711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
